B+
Bull case
25%
Probability
Target price
$0.55
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
SILO
SiloFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The supported bull case is narrow: SILO still has a defined lead asset path, and the latest 10-K indicates enough cash for at least twelve months from March 27, 2026 while SPC-15 advances toward a possible 2026 IND filing [#10-K-2026-03-27].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Clinical and regulatory timing risk around SPC-15, including whether IND-enabling work converts into an actual 2026 IND filing.
Momentum
47
Value
59
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.42 · Bull $0.55 · Bear $0.24Analysis 2026-05-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Why
Momentum47 · Δ7d -
Value59 · Δ7d +0.0
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta +0.0.
Contradictions & invalidation
- • Clinical and regulatory timing risk around SPC-15, including whether IND-enabling work converts into an actual 2026 IND filing.
- • Future financing and dilution risk remains high despite the 10-K's twelve-month liquidity statement because SILO is still a development-stage micro-cap biotech.
- • The bear case remains stronger on visibility: no confirmed Q1 2026 earnings release, 10-Q, or earnings 8-K was located in recent SEC filings through May 9, 2026, analyst target/revision coverage is absent, and the company now carries added execution and dilution questions from the QwikAgents transaction [#8-K-2026-04-02].
Catalyst clock
2026-06-30
Non-core QwikAgents acquisition adds strategy and dilution scrutiny
Lead driver: Value · See fundamentals
Momentum
47
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
59
28% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.3
Sentiment
0
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 46.6 / Value 58.6 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-09. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.42
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.24
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$4.88M
Beta
0.60
Shares Out
1.25M
P/E (TTM) · Derived
-0.5
P/S (TTM)
65.38
P/FCF (TTM) · Derived
-0.97
Rev YoY
-100.0%
EPS YoY
-73.6%
Gross Margin
-1329.3%
Op Margin
-6631.3%
Net Debt
-$6.86M
Current Ratio
5.36
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data